Streetbeat News

Revenues

PROF

Profound has reiterated its guidance for 2024, expecting total revenue to be in the range of $11.0 million to $12.0 million, which represents a year-over-year growth of 53% to 67%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:55 pm

SSIC

Silver Spike Investment (NASDAQ:SSIC) reported Q2 2024 GAAP EPS of $0.21 and sales of $3.081 million, significantly beating the analyst consensus estimate of $1.970 million. This represents a 160.88% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:54 pm

HYPR

Hyperfine has raised its revenue expectations for FY24 to $13-$16 million, reflecting a year-over-year growth of 31% at the midpoint. The company maintains its cash burn estimate at approximately $40 million for the year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:54 pm

GROV

Grove has revised its FY24 net revenue outlook downwards from $215M-$225M to $205M-$215M, which is below the estimated $219.868M. However, the company has increased its adjusted EBITDA margin forecast to 0.5%-1.5% from the previous 0%-1.0%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:54 pm

TACT

TransAct Technologies has projected its FY24 net sales to be between $45 million and $50 million, compared to the $46 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:53 pm

SEER

Seer Inc. has revised its FY24 revenue guidance to $13M-$15M, which is below the previous estimate of $16.7M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:52 pm

AWX

Avalon Holdings reported a significant improvement in its Q2 earnings per share (EPS), which rose to $0.24 from a loss of $(0.04) year-over-year. The company's revenue also increased to $23.1 million from $20.8 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:52 pm

FRD

Friedman Industries reported Q1 sales of $114.55 million and an EPS of $0.37.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:52 pm

APYX

Apyx Medical has adjusted its FY24 total revenue outlook to a range of $50.6M - $52.1M, up from the previous range of $49.7M - $52.9M. The new estimate is slightly above the consensus estimate of $49.99M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:51 pm

ORGO

Organogenesis Holdings (NASDAQ:ORGO) reported Q2 sales of $130.234 million, surpassing the analyst consensus estimate of $121.850 million by 6.88%. This represents an 11.01% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:48 pm